A Multicenter Adaptive Randomized Controlled Platform Trial of the Safety and Efficacy of Antithrombotic Strategies in Hospitalized Adults with COVID-19
Brief description of study
Patients with COVID-19 disease are at risk of blood clots, which may affect many parts of the body. The purpose of this study is to determine if a higher dose blood thinner is better than a lower dose blood thinner in patients hospitalized with COVID-19 disease. The blood thinners used in this study are heparin-related medicines. They are already approved by the United States Food and Drug Administration (FDA) for preventing blood clots in different situations. Currently it is not known the best dose of these drugs in people hospitalized with COVID-19.
Clinical Study Identifier: s20-01439
ClinicalTrials.gov Identifier: NCT04505774
If you are registered as a volunteer, please log in to contact the study team/express interest in this study.
